LUND, Sweden, Oct. 17, 2022 /PRNewswire/ -- Immunovia AB
(Nasdaq: IMMNOV) (Stockholm:
IMMNOV) today announced that it enters into a strategic partnership
with Proteomedix to leverage its substantial joint development
experience in diagnostic technologies for the detection of cancer.
This will enable increased R&D productivity for Immunovia as
the Company continues to strengthen its commercial development in
the US.
The partnership between Immunovia and Proteomedix leverages the
companies' complementary R&D capabilities and advances their
R&D efforts. With this partnership, Immunovia will gain a more
flexible R&D organization, increase its R&D productivity,
and will focus internal resources on the commercial build up, thus
further accelerating the roll-out of IMMray™ PanCan-d. The
partnership capitalizes on the combined expertise of two leading
innovators in proteomics-based diagnostics, who have both launched
innovative oncology tests, Immunovia with IMMray™ PanCan-d in the
U.S. and Proteomedix with Proclarix® in
Europe.
Proteomedix, a Swiss-based Company, was founded 2010 as a
spin-off company of ETH Zurich to bring together the expertise of a
multi-disciplinary group of world-leading scientists and clinicians
in proteomic-based diagnostics. The Company is focused on research
and development that relies on a network of clinicians, IVD
experts, laboratories, and marketers. Proteomedix has developed a
blood-based prostate cancer test using proteomics technology that
measures cancer-associated proteins, using highly reproducible
immunoassays.
"We are very excited to enter this partnership with Immunovia,
an early-commercial company like us with an innovative diagnostic
test in oncology. This partnership enables both companies to faster
take critical steps forward by leveraging our combined expertise to
increase R&D efficiency. For Proteomedix, this partnership
demonstrates how our biomarker assay development expertise can be
deployed beyond prostate cancer," said Helge Lubenow – CEO, Proteomedix.
"Immunovia is entering a new phase with an increased focus on
the commercialization of our IMMray™ PanCan-d test in the US while
maximizing our R&D productivity. This partnership with
Proteomedix will combine leading proteomics-based researchers with
state-of-the art capabilities from both companies to create an
outstanding R&D platform," said Philipp
Mathieu – CEO and President, Immunovia.
In connection with the new R&D partnership, Linda Dexlin
Mellby, Vice President Research & Development at Immunovia,
will be leaving the company as of 4 November.
"Linda has been instrumental in the development of Immunovia's
IMMray™ PanCan-d test over the past nine years. We thank her for
her many contributions to the company and wish her all the best in
her future endeavors," continued Philipp
Mathieu – CEO and President, Immunovia.
For more information, please contact:
Philipp Mathieu
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
The information in this report is information that Immunovia
AB is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact person set out above,
at 08:30 am CET on October 17,
2022.
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit https://immunovia.com/
About Proteomedix
Proteomedix is a healthcare company whose mission is to
transform prostate cancer diagnosis. The company has identified
novel biomarker signatures with utility in prostate cancer
diagnosis, prognosis and therapy management. The lead product
Proclarix® is a blood based prostate cancer test
panel and risk score currently available in Europe. Proteomedix is located in the
Bio-Technopark of Zurich-Schlieren, Switzerland. For more information,
visit www.proteomedix.com.
The following files are available for download:
https://mb.cision.com/Main/13121/3649124/1639362.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-launches-a-strategic-partnership-with-proteomedix-to-leverage-rd-efforts-with-increased-focus-on-commercialization-301650498.html